Drug Detail

Information about NB003

Generic Name
IND
 NB003
Brand Name (US)
Manufacturer
 Ningbo Newbay
Drug Type
 Tyrosine Kinase Inhibitor
Delivery
 Oral
Approval Status
 Phase 1
Indications
Overall Strategy
 KIT and PDGFRA protein based
Strategy
 Inhibit KIT and PDGFRa
Drug Category
 KIT/PDGFRA inhibitor

Links

 

 Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors
   

 

 The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
   

 

 Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
   

Trials of this drug

  

 A Study of NB003 in Patients With Advanced Malignancies
   

Trial results

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed